MR
Highly rated in
8
conditions
Highly rated in
8
conditions
Check Dr. Margaret V. Ragni's experience treating your condition:
About Dr. Margaret V. Ragni

Margaret Ragni is a Hematologist in Pittsburgh, Pennsylvania. Ragni has been practicing medicine for over 47 years and is highly rated in 8 conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Hemophilia B, Knee Replacement, and Hip Replacement. She is licensed to treat patients in Pennsylvania.

Her clinical research consists of co-authoring 156 peer reviewed articles and participating in 23 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Margaret V. Ragni it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
Pittsburgh, PA 15213
Other Locations
5115 Centre Avenue, Floor 5, Pittsburgh, PA 15232
Background & Education
Graduate Institution
University Of Pittsburgh School Of Medicine, 1975
Specialties
Hematology
Licenses
Specialist in PA
Hospital Affiliations
Punxsutawney Area Hospital
UPMC Magee-Womens Hospital
Uniontown Hospital
UPMC Presbyterian
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


22 Clinical Trials

Natural History Study of Factor IX Treatment and Complications
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease
Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP
View 18 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors